Ductal adenocarcinoma, the most common form of pancreatic cancer in humans, is associated with activation of the K-ras oncogene in ~90% of cases. In contrast, K-ras mutations are found in <50% of the relatively rare intraductal papillary mucinous tumor (IPMT), which arises in the main pancreatic ducts. Since both adenocarcinomas and IPMTs are believed to arise from ductal cells and progress through similar sequences of morphological changes (i.e. flat hyperplasia, papillary hyperplasia, atypia and carcinoma in situ), it is clear that such progression may not always necessitate activation of the ras oncogene. Experimentally ductal adenocarcinomas of the pancreas can be induced in the hamster model by a brief treatment with A r -nitroso(2-hydroxypropyl)(2-oxopropyl)amine (HPOP), while IPMTs can be induced by a combined treatment with HPOP and orotic acid (OA) in an initiation/ promotion schedule. Since animals are exposed to the carcinogen only once, initiated normal epithelium is expected to give rise to a wide spectrum of neoplastic and preneoplastic lesions, progression of which will depend on the extent of mutagenesis induced at initiation in the targeted cells. In order to investigate the role of K-ras in progression of IPMTs as compared with adenocarcinomas we have examined the presence of K-ras mutations in the above two types of experimentally induced pancreatic cancers, as well as in associated and preneoplastic lesions. K-ras mutations at codons 12, 13 and 61 were determined by a designed restriction fragment length polymorphism method using mismatched nested primers in 77 neoplastic and preneoplastic foci microdissected from 20 pancreases. Mutations were found in all foci of atypical hyperplasia, in carcinomas in situ and invasive cancer, whether such lesions originated in lobular tissue or in the main pancreatic duct. Mutations were also found in papillary hyperplasia and flat hyperplasia in small ducts and also in the main duct at high frequency. With one exception, all ras mutations were G->A transitions at the second base of codon 12. Mutations were occasionally accompanied by excessive presence of the mutant ras allele or loss of the wild-type ras allele, events that were more frequent in
Introduction
The ras mutation is the most frequent of the known genetic changes in ductal adenocarcinoma of the pancreas, with an incidence of 75-95% (1). The mutations, mainly in codon 12 of the K-ras gene, occur at much higher frequency than those found in any other tumor type (2) , suggesting that mutations in the K-ras gene play an important role in pancreatic carcinogenesis. Furthermore, K-ras mutations are early events in the development of pancreatic cancer in man, since they have been found in hyperplastic changes associated with pancreatic adenocarcinomas (3) . Recently K-ras mutations have been reported in the development of mucous hyperplasia in patients suffering from chronic pancreatitis (4) . However, such involvement has not been generally accepted (3, 5) . Activation of Ras oncoproteins may not be the only mechanism for transforming ductal cells of the pancreas into an over-populated hyperplastic, frequently papillary ductal epidielium. Examination of several cases of a distinct form of ductal cancer of the pancreas, known as intraductal mucinous papillary tumors (IMPTs*), and by various other names (6) (7) (8) (9) (10) (11) , indicated that K-ras mutations are relatively infrequent in such tumors, regardless of the developmental stage. Although the reported incidence of K-ras mutations in IPMTs varies considerably, the overall K-ras incidence of 44% (12) is markedly lower than the 75-95% incidence reported for adenocarcinomas. In order to study the role of ras mutations in the development of aggressive adenocarcinomas and also of other ductal tumors we have investigated the appearance of K-ros mutations in the ductal and ductular epithelium of the hamster pancreas following exposure to pancreatropic nitrosamines. Continuous administration of A / -nitroso-(2-hydroxypropyl)(2oxopropyl)amine (HPOP) for 9 days to female hamsters followed by 30 weeks of 20% protein synthetic diet results in a 67% incidence of multifocal induction of adenocarcinomas and preneoplastic lesions of ductular origin in the body of the gastric lobe of the pancreas (13) . In contrast, a 28 week promotion of HPOPinitiated female hamsters with orotic acid (OA) 2 weeks after initiation results in induction of a large incidence of preneoplastic lesions in the common and main pancreatic ducts and less frequently in the lobules (14) . These two regimens have been employed to induce both ductular adenocarcinomas and IPMTs. Since carcinogen administration is limited to a brief time span, mutations needed to initiate various lesions are directed toward the normal epithelium of the hamster pancreas and not toward already transformed cells from previous carcinogenic treatments, as may be the case with repeated exposure to carcinogen in other models for pancreatic carcinogenesis (15, 16) . Variations in the severity of lesions, therefore, are expected to be the result of the extent of mutations inflicted on cells before clonal expansion to yield transformed foci and lesions, rather than to the age of the lesion. We consider that the hamster-HPOP model is most suitable for the study of mutations required to induce various stages of tumor progression. In this communication, processes leading to both ductal adenocarcinomas and IMPTs are characterized in terms of acquisition of ras mutations.
Materials and methods

Tissues
We used paraffinized blocks of pancreas and liver obtained from a previous study (14) as a source of seemingly normal and also neoplastic tissue. In that study female hamsters were treated with 19 mg/kg/day HPOP over a period of 9 days and fed: (i) a synthetic diet containing 20% casein for 30 weeks, at which time they were killed; (ii) a synthetic diet containing 20% casein for 2 weeks after HPOP treatment, followed by a similar diet supplemented with 1% OA for 28 weeks before death. Serial sections 5 |lm thick were cut from paraffinized blocks. All slides in the series were stained with hematoxylin and eosin (H&E). Every first slide was covered with a cover slip and examined to identify preneoplastic and neoplastic lesions. Other slides lacking cover slips were used for microdissection.
Microdisscction of materials from stained slides and DNA extraction
We utilized a modification of a previously described microdissection technique (17) to collect precisely identified groups of cells under direct microscopic observation, using an inverted microscope with a joystick-operated hydraulic micromanipulator (Nikon-Narishige). We microdissected 50-300 cells in each area. Dissected foci included preneoplastic and neoplastic lesions and histologically normal ductal, acinar, islet and stromal lymphocytes. Lymphocytes were also dissected from each slide and used as internal controls. Preneoplastic and neoplastic lesions from the liver, gall bladder and bile duct, which are also induced by HPOP at a low incidence in hamsters, were also sampled (14) . The dissected cells were allowed to adhere to the jagged edge of the microcapillary tip and were collected in 0.5 ml siliconized microcentrifuge tubes. The materials were digested in 10-20 nl 20 mM Tris, pH 8.0, 1 mM EDTA, 0.5% Tween 20, 200 ng/ml proteinase K buffer for 24-36 h at 42°C and then incubated for 15 min at 95°C to inactivate proteinase K. Five microliters of the digested samples, which included at least 50 cells, were used for each PCR reaction as template DNA. Mixing experiments using cell lines having mutant and wild-type forms (data not shown) have demonstrated that the assay is sensitive enough to detect one mutant cell per 10-to 20-fold excess of wild-type cells in a total cell population >50.
PCR and designed restriction fragment length polymorphism (RFLP) analysis to detect K-ras mutations
Exons 1 and 2 of the K-ras gene were amplified by hemi-nested PCR methods similar to those developed for analysis of the human ras gene (17) . The assays were performed in two steps: (i) a screening designed RFLP test to detect point mutations in codons 12, 13 and 61 of the K-ras gene; (ii) further designed RFLP tests to identify specific point mutations indicated by the screening test. Primers used for the first step are shown in Table I . Cell lines previously identified as having ras mutations were used as positive controls (17, 18) .
The first PCR reaction was performed in a 50 fll reaction mixture with 5 \x\ template DNA in a thermal cycler (Perkin-Elmer Cetus 9600) with an initial 94°C denaturation step for 4 min followed by 35 cycles of denaturation at 94°C for 20 s, annealing at 55°C for 20 s and extension at 72°C for 20 s, with a final extension of 7 min at 72°C. The first PCR product was diluted 1:100 in dH 2 O and 1 u.1 of the dilution was used as template for the second PCR reaction. The latter was performed using a mismatched sense primer in 20 (il reaction mixture with the same contents as the first PCR and 30 cycles were used. The inner mismatched primers introduce a new restriction site into the PCR product derived from a normal allele. The restriction site is BstN\ for codon 12, BgR for codon 13, flc/I for the first two bases of codon 61 and Earl for the third base of codon 61. Ten microliters of the second PCR product were digested in a volume of 100 |il with 7-10 U of one of the restriction enzymes, under conditions recommended by the suppliers. Then DNA was electrophoresed with //aelll-digested <{i X 174 RF DNA size markers and the bands visualized under UV light after ethidium bromide staining and photographed. Wild-type alleles were digested by the enzyme and yielded a smaller product than the digestion-resistant mutant bands. Digestion was always complete, as determined from negative internal controls (lymphocytes) run simultaneously in each experiment. Whenever the internal standards showed evidence of incomplete digestion all samples were discarded and the experiment was repeated.
If a mutant band was identified by the first screening step, the second step was performed to identify the specific base substitution. The primers and steps utilized were identical to those used for identification of mutations in the human ras gene (17) .
Results
Seventy seven separate neoplastic lesions from 20 female hamsters were examined. Tissues were dissected from five ductal adenocarcinomas and four carcinomas in situ arising from small ducts of the pancreases of the five hamsters treated with HPOP alone. Tissues from cholangiocarcinomas and cholangiomas were also collected from the same animals. Samples of IMPTs and precursor lesions, ranging from fiat hyperplasia to papillary tumors, were obtained from 15 hamsters treated with HPOP and OA in an initiation-promotion regimen previously described (14) . The IPMTs induced in the hamster model bear an uncanny resemblance to human IPMTs, as shown in Figure 1A and B. In addition to the above, 51 samples of seemingly normal duct, acinar, islet and lymph tissue were dissected from the 15 hamsters treated with HPOP and OA and analyzed for ras mutations. Such tissue samples were both adjacent to and distant from neoplastic lesions or tumors. A smaller number of samples were dissected from the liver and gall bladder of animals which, in addition to pancreatic cancer, also had tumors in these sites.
Incidence of K-ras mutations
Microdissected foci were screened for the presence of mutations in codons 12, 13 and 61 using the designed RFLP method. All microdissected materials provided suitable template DNA for use in PCRs, resulting in amplification of a 99 bp product in the second PCR specific for codon 12 of the Kras gene. Wild-type forms were digested, resulting in a band 79 bp in size. Mutant alleles resulted in BstHl digestionresistant bands 99 bp in size (Figure 2 ). Screening for mutations Table  II . All microdissected foci of stromal lymphocytes, islet cells, acinar cells and normal ducts had a wild-type K-ras gene. Four foci of ductular proliferation were identified and microdissected from two pancreases and one of these four foci was positive for a codon 12 mutation. Ten foci of flat hyperplasia were obtained from three animals. Four samples were collected from the common duct and six from the main duct. Six of these 10 lesions had a codon 12 mutation, with mutant frequency being greater in the main than in the common duct. Twenty foci of papillary hyperplasia were obtained from seven hamsters with the lesion. Eighteen of the 20 foci were positive for codon 12 mutations. The mutation was present in all foci of papillary hyperplasia of the common pancreatic duct, while it was absent in the main pancreatic duct of one of the animals in which cell proliferation was focal. All foci of atypical hyperplasia, carcinoma in situ and invasive adenocarcinoma had a codon 12 mutation. These included five cases of ductal adenocarcinoma from five animals, five cases of papillary invasive cancer arising from the main pancreatic duct from five animals, four cases of carcinoma in situ arising in small ducts in three animals and 10 cases of intraductal carcinoma in situ arising in the main pancreatic duct from five animals. No mutations in codons 13 and 61 were found.
Identification of specific K-ras mutations
With one exception, all lesions had a G-»A transition at the second base of codon 12, resulting in a glycine to aspartic acid substitution. One focus of flat hyperplasia had a GGT-»GTT mutation in codon 12, which leads to a glycine to valine substitution.
The pattern of K-ras mutations
The designed RFLP method made possible simultaneous visualization of both mutant and normal alleles in heterozygous cell populations ( Figure 3 ) and permitted an estimation of the ratio of mutant to wild-type alleles. The microdissection method also permitted precise collection of cells from histopathologically identified foci without contamination by other cell types. Thus the ratio of mutant to wild-type bands was not skewed by the presence of stromal or other cells present in analyses of gross tumor samples. The patterns present in mutant ros-containing human tumors and cell lines have been previously classified into three groups (17) . In pattern I the PCR products corresponding to the wild-type and mutant forms are of similar intensities. In pattern Ha the mutant band is in great excess (relative increase). In pattern lib the wild-type band cannot be identified (absolute increase). This latter pattern was rare in hamsters, shown only in two out of 77 identified mutations. Therefore, in the hamster model patterns Ila and lib were classified as pattern II, denoting excess of the mutant over the normal allele. Pattern I was the most common pattern seen, including all foci of ductular proliferation and flat hyperplasia with the mutation. Pattern II was seen mostly in histopathologically more advanced lesions. This pattern was more frequent in atypical hyperplasia or invasive cancer than flat or papillary hyperplasia (Table II) .
Tumors in other sites
In the hamster-HPOP model lesions were induced primarily in the pancreas. There was a low incidence of liver tumors (cholangiomas and cholangiocarcinomas), gall bladder tumors (adenocarcinomas) and bile duct proliferative changes (hyperplasia). These lesions were also examined for K-ras mutations (Table II) . The K-ras mutations at these sites were only in codon 12 and were characterized as G-»A transitions. The frequency of mutation in cholangiocarcinomas was greater than in cholangiomas. Mutations were absent in gall bladder adenocarcinomas in the two cases examined. Bile duct hyperplasia was associated with K-ras mutation in the one case studied. All cholangiocarcinomas showed pattern II mutation. 
Discussion
The frequent presence of K-ras mutations in pancreatic ductal adenocarcinomas and accompanying preneoplastic lesions (3, 19) underlines the importance of this oncogene in pancreatic carcinogenesis as an early stage event. In contrast to adenocarcinomas, a group of pancreatic neoplasms arising in the main duct, known by various names such as intraductal papillary carcinoma, mucus hypersecreting carcinoma, mucinous ductal ectasia or papillary cystadenoma (6-11), depending on the stage of their development (20) , have been shown to have a markedly lower incidence of K-ras mutations. The exact incidence of K-ras mutations in such tumors, collectively known as IMPTs (12), cannot be estimated from the reported studies (4, 5, 12, 21, 22 ), but appears to be no greater than 50% of all the cases tested (Table III) . Furthermore, the presence of K-ras mutations in human IPMTs is random, with no apparent correlation between morphology, stage of malignancy, site of tumor, sex or age of patients (12) .
In the hamster model a high incidence of papillary neoplasms with a morphology very similar to human IPMTs has been induced with an initiating regimen of HPOP followed by promotion with OA (14) . In contrast to the A'-nitroso(2-oxopropyl)amine (BOP) model, preneoplastic lesions, particularly in large ducts of the pancreas, are not extensions of large tumors and most probably represent the site of tumor initiation. Various degrees of growth of papillary neoplasms in the large ducts of the hamster pancreas result in a variety of preneoplastic lesions informative of the overall carcinogenic process. The heterogeneity of preneoplastic lesions in this model is probably due to the different capacity of component cells of the lesion to progress through malignant transformation, rather than the variable times of initiation, as may be the case in humans. This is concluded from the general failure of such lesions to give rise to cancer, regardless of the time the hamster is kept alive over a 30 week period after initiation (D.M.Kokkinakis, unpublished observation). The action of OA is not well understood (23, 24) , but it is theorized that it probably inhibits growth of normal ductal epithelium, allowing mutated cells to expand and give rise to focal hyperplasia and subsequently to extensive papillary lesions (14) . The K-ras mutation could possibly render the cell resistant to the mito-inhibitory effect of OA and allow growth of tumors which subsequently carry the K-ras mutant phenotype. This could explain the presence of K-ras mutations in all intraductal tumors invading surrounding tissue and in all dysplastic lesions. It does not, however, mean that all lesions having the K-ras mutation can progress to cancer, as is evident from the wide variety of early lesions, in spite of the presence of the mutation.
The incidence of ras mutations found in both neoplastic and preneoplastic lesions in this study is considerably higher than that reported in the BOP model by other investigators (25, 26) . The higher incidence may be due to: (i) the use of HPOP instead of BOP; (ii) the use of female hamsters instead of the male animals employed in previous studies; (iii) the use of a promoting regimen which may be specific in selecting Kros mutants. The difference between BOP and HPOP is that the former is activated to yield a methylating agent, while the latter yields both methylating and 2-hydroxypropylating species (27) . Although BOP is converted to HPOP in a reaction catalyzed in many tissues, including the pancreas and its ductal components (28) , the ratio of methyl to hydroxypropyl adducts is 10 times higher in the pancreas of hamsters treated with BOP than in those treated with HPOP (29) . A similar situation should be true in the ductal component of the pancreas, since in duct cell cultures the ratio of CAmethylguanine to O 6 -(2-hydroxypropyl)guanine following treatment with BOP and HPOP is seven and two respectively (28) .
Hydroxypropylation of DNA results in G->A mutations via formation of die O 6 -(2-hydroxypropyl)guanine adduct (30) . Furthermore, the yield of such mutations induced by the above adduct is at least four times greater than that induced by C^-methylguanine under conditions which yield a similar concentration of the above promutagenic lesions (30) . In the hamster-HPOP model O 6 -(2-hydroxypropyl)guanine is repaired more slowly and persists longer than O^methylguan-ine, allowing a greater window of opportunity for mutation in K-ras (31) . The use of female hamsters instead of male animals used in previous studies may also have affected the number of K-ras-positive foci and the continuous growth of such foci to sizable lesions. Growth of pancreatic tumors has been shown to be estrogen dependent (32) and can be inhibited by the estrogen competitor tamoxifen (33) . Thus the effect of estrogen on selective growth of cells having a mutation in K-ras is probable and should be investigated further. Another source of the high incidence of K-ras mutations in this study may be selection of K-ras mutants by the promoting regimen. Although a direct relation between resistance to OA-induced mitoinhibition and K-ras mutation has not been demonstrated, it has been observed that OA enhances the rate of appearance of hyperplastic K-ras-positive lesions in the common and main pancreatic ducts of the hamster pancreas as early as 3 weeks after initiation of the promoting regimen (D.M.Kokkinakis, unpublished observations). However, the similar incidence of K-ras mutations observed in HPOP-treated animals without OA promotion argues against the last possibility. Further examination of the BOP-hamster model in parallel with the models used here is needed in order to identify the mechanisms by which pancreatic preneoplastic lesions progress to invasive cancer without K-ras involvement. If, indeed, the triggering of a ras-induced mitogenic pathway via ras mutation is not an absolute requirement for rapid growth of pancreatic cancers, the question arises whether or not other sites in that pathway are affected by carcinogen-induced mutations resulting in similar mitotic activity.
With the exception of a single focus, the specific mutation found in preneoplastic and neoplastic lesions of both ductal and ductular origin was always a transition at the second position of codon 12 of the K-ras gene, specifically a GGT (Gly)-»GAT (Asp) change. An identical mutation has been described in the BOP model (25, 26) . In human IPMTs a G-»A transition is the most common mutation, reported in five out of eight cases by Sessa (12) and in four out of five cases by Yanagisawa (4) . A G->A transition is also the most common mutation in human ductal adenocarcinomas, found in 48% of all cases according to Hurban (19) . The almost exclusive G-)A transition observed in the hamster model is in agreement with the mechanisms of carcinogen action yielding C^-methylguanine and O 6 -(2-hydroxypropyl)guanine adducts, which remain unrepaired for prolonged time periods (31) .
A correlation between the ratio of mutant to wild-type Kras alleles and the degree of neoplasia was evident in these studies. An increase in this ratio has been observed in hyperplasia associated with atypia, in carcinoma in situ and in cancer. Complete loss of the wild-type allele was observed in two cases of adenocarcinoma, but was never seen in IPMTs and related preneoplastic lesions. The above indicate that in the hamster model, as in humans (17), progression through the various stages of hyperplasia to carcinoma in situ and cancer may depend on the relative ratio of mutant to wild-type alleles. However, in the absence of further evidence, caution should be exercised not to overestimate either the mutation itself or the relative increase in the mutant allele as a requirement for initiation and progression of pancreatic cancer in the hamster model. The guanine at the second position of K-ras codon 12 is particularly sensitive to carcinogen-induced mutation for several reasons, including enhanced adduct formation (34) , diminished repair by C^-methylguanine-DNA alkyltransferase (35) and enhanced mispairing with thymidine during DNA replication (36) . Thus, in the absence of easily induced K-ras mutations, the level of other mutations possibly required for pancreatic carcinogenesis may be insufficient to result in malignant transformation of targeted cells beyond the stage of flat or papillary hyperplasia. The progression may stop at that particular stage for the rest of the animal's life, providing that the frequency of spontaneous mutations is not sufficient to change that status.
In conclusion, unlike human IPMTs, which seem to develop without an absolute requirement for K-ras activation, in the hamster model the full progression from papillary hyperplasia to intraductal papillary tumors morphologically similar to human IPMTs appears to involve such activation and perhaps partial loss of the wild-type allele. In this respect, development of human and hamster IPMTs may not be mediated by exactly the same mechanism, although the possibility of mutations in oncogenes downstream from ras in the same pathway of activation of cell proliferation cannot be ruled out at this time. Certainly the presence of K-ras mutations in a significant number of, but not all, human IPMTs may result from more than one etiology or induction mechanism. A certain fraction of such tumors could arise by early activation of K-ras in a fashion similar to that seen in the hamster model and could be related to the action of chemical carcinogens.
